Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PS-341 (Bortezomib) in Metastatic Neuroendocrine Tumors
NCT00017199Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Apr 2001
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in neuroendocrine tumors (NETs), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Apr 2001; status: completed.
02
Drugs
bortezomib
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT00017199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00017199.